This study is in progress, not accepting new patients
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
a study on Lung Cancer Solid Tumor Head and Neck Cancer Pancreatic Cancer Ovarian Cancer Kidney Cancer Renal Cell Carcinoma Glioma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UCLA UCSD UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Five Prime Therapeutics, Inc.
- ID
- NCT02526017
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated